In the BioHarmony Drug Report Database

"Preview" Icon

Enfortumab vedotin-ejfv

Padcev (enfortumab vedotin) is an antibody pharmaceutical. Enfortumab vedotin was first approved as Padcev on 2019-12-18. It is used to treat urinary bladder neoplasms in the USA. The pharmaceutical is active against nectin-4.

 

Trade Name

 

Padcev
 

Common Name

 

enfortumab vedotin
 

ChEMBL ID

 

CHEMBL3301589
 

Indication

 

urinary bladder neoplasms
 

Drug Class

 

Synthetic analogs of the dolastatin series; monoclonal antibodies: fully human, tumors as target

Image (chem structure or protein)

Enfortumab vedotin-ejfv structure rendering